Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olezarsen in hypertriglyceridemia with ASCVD risk or severe hypertriglyceridemia
NL-OMON59221Phase 3Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jun 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertriglyceridemia comparing Olezarsen with Placebo (2 arms). Primary endpoint: Percent change in fasting triglycerides at Week 25. Started Jun 2023; status: completed.
02
Drugs
olezarsen
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NL-OMON59221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59221.